Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 10 May

Grady Wulff
May 10, 2024

Morning Bell 10 May

Sam Kanaan
May 10, 2024

Morning Bell 9 May

Grady Wulff
May 9, 2024

Morning Bell 8 May

Grady Wulff
May 8, 2024

Morning Bell 7 May

Sam Kanaan
May 7, 2024

Morning Bell 6 May

Grady Wulff
May 6, 2024

Weekly Wrap 3 May

Sophia Mavridis
May 3, 2024

Morning Bell 2 May

Sophia Mavridis
May 2, 2024

Morning Bell 1 May

Grady Wulff
May 1, 2024

Morning Bell 30 April

Grady Wulff
April 30, 2024

Morning Bell 29 April

Grady Wulff
April 29, 2024

Morning Bell 26 April

Sam Kanaan
April 26, 2024